Clinical Trials Browser

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05850273 2025-02-04

IFN&SMP

Recruiting

80 enrolled

Myeloid

Myeloproliferative Disorders

NCT03869476 2024-12-30

BioScoreSMP

Phase NA Completed

133 enrolled

Myeloid

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT03493646 2024-05-28

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Phase 2 Completed

40 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06022341 2023-09-01

MOZART

Phase NA Not yet recruiting

120 enrolled

Myeloid

Myeloproliferative Disorders

NCT02381379 2020-09-14

MSIT

Phase 3 Unknown

118 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02161978 2019-11-06

DYVA-AAGG

Completed

93 enrolled

MyeloidOther hematologic neoplasm

Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03062436 2019-07-23

To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission

Phase NA Unknown

27 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03978364 2019-06-07

A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

Phase 3 Unknown

100 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02115672 2016-08-15

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00750659 2016-04-20

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Phase 2 Completed

24 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01542944 2016-04-20

TevaGastrim for Stem Cell Mobilization Sibling Donors

Phase 2 Completed

24 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00491634 2015-12-02

Treosulfan-based Conditioning for Transplantation in AML/MDS

Phase 2 Completed

24 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01339988 2011-04-21

Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

Phase 4 Unknown

10 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Juvenile

NCT00297570 2007-10-10

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Phase 3 Unknown

90 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

CELESTIAL-MDS

BioPredictor

PHEMOP

ED2024

Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

PALERMO

PTCy and ATG for MSD and MUD Transplants

IFN&SMP

BioScoreSMP

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

MOZART

MSIT

DYVA-AAGG

To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission

A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

TevaGastrim for Stem Cell Mobilization Sibling Donors

Treosulfan-based Conditioning for Transplantation in AML/MDS

Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy